Wedbush Securities Inc. bought a new stake in Aquestive Therapeutics Inc (NASDAQ:AQST) in the 2nd quarter, according to its most recent filing with the SEC. The fund bought 70,733 shares of the company’s stock, valued at approximately $297,000. Wedbush Securities Inc. owned 0.28% of Aquestive Therapeutics at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. BlackRock Inc. lifted its stake in shares of Aquestive Therapeutics by 36.1% in the 4th quarter. BlackRock Inc. now owns 641,800 shares of the company’s stock valued at $4,042,000 after purchasing an additional 170,396 shares during the period. Squarepoint Ops LLC acquired a new position in shares of Aquestive Therapeutics in the 4th quarter valued at $188,000. Geode Capital Management LLC lifted its stake in shares of Aquestive Therapeutics by 77.6% in the 4th quarter. Geode Capital Management LLC now owns 44,208 shares of the company’s stock valued at $278,000 after purchasing an additional 19,310 shares during the period. Millennium Management LLC acquired a new position in shares of Aquestive Therapeutics in the 4th quarter valued at $145,000. Finally, Spark Investment Management LLC acquired a new position in shares of Aquestive Therapeutics in the 1st quarter valued at $80,000. Hedge funds and other institutional investors own 66.42% of the company’s stock.
NASDAQ:AQST traded up $0.29 during trading hours on Friday, reaching $3.81. 24,300 shares of the company were exchanged, compared to its average volume of 70,076. The company has a debt-to-equity ratio of 4.23, a quick ratio of 1.40 and a current ratio of 1.59. The stock’s 50-day moving average is $3.99 and its 200-day moving average is $5.31. Aquestive Therapeutics Inc has a twelve month low of $2.96 and a twelve month high of $20.70.
Several equities analysts recently issued reports on the stock. Wedbush set a $31.00 target price on shares of Aquestive Therapeutics and gave the company a “buy” rating in a research note on Friday, July 5th. ValuEngine upgraded shares of Aquestive Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Zacks Investment Research upgraded shares of Aquestive Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, August 12th. Finally, HC Wainwright began coverage on shares of Aquestive Therapeutics in a research note on Monday, April 22nd. They issued a “buy” rating and a $10.00 target price for the company. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Aquestive Therapeutics presently has an average rating of “Buy” and a consensus price target of $19.54.
Aquestive Therapeutics Company Profile
Aquestive Therapeutics, Inc, a specialty pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery in the United States and internationally.
Recommended Story: Real Estate Investment Trust (REIT) ETF
Receive News & Ratings for Aquestive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquestive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.